TeraRecon Joins ConcertAI Family to Streamline SaaS Research and Bolster RWE Studies

November 10, 2021

ConcertAI reported the addition of TeraRecon to its portfolio in an agreement intended to support clinical decision-making. The software-as-a-service (SaaS) company will bring expertise in real world data (RWD), including electronic health records and genomic data, and support high-level clinical research and regulatory submissions.

ConcertAI CEO Jeff Elton remarks, “With the FDA’s recent guidance on RWD for regulatory decision-making, ConcertAI is the only oncology, hematology, and urology-focused company capable of integrating primary data sources for the critical assessment of patient response and safety,” adding, “It is anticipated that 100% of regulatory submissions in oncology will integrate real-world evidence [RWE].” Read more here.

(Source: ConcertAI, 11/9/21)

Share This Story!